Novartis Reports Phase 2 Data for Nivolumab in Breast cancer

Novartis today announced Phase 2 results for Nivolumab in patients with Breast cancer. The study demonstrated that Nivolumab reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of Breast cancer and support the continued development of Nivolumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Nivolumab was consistent with previous observations, with no new safety signals identified.